Profile data is unavailable for this security.
About the company
Eagle Pharmaceuticals, Inc. is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial capabilities. The Company is focused on developing medicines that result in improvements in patients' lives. The Company's commercialized products include vasopressin, PEMFEXY, RYANODEX, BENDEKA, BELRAPZO, TREAKISYM (Japan), and BYFAVO and BARHEMSYS through its wholly owned subsidiary Acacia Pharma Inc. Its oncology and central nervous system (CNS)/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states. The Company also has a research and development facility in Cambridge, Massachusetts. The Company has office space in Palm Beach Gardens, Florida and Indianapolis, Indiana. The Company’s subsidiaries include Eagle Biologics, Inc., Eagle Research Lab Limited, Acacia Pharma Group plc, Acacia Pharma Limited and Acacia Pharma Inc.
- Revenue in USD (TTM)257.55m
- Net income in USD11.95m
- Incorporated2007
- Employees134.00
- LocationEagle Pharmaceuticals Inc50 Tice Boulevard, Suite 315WOODCLIFF LAKE 07677United StatesUSA
- Phone+1 (201) 326-5300
- Fax+1 (302) 655-5049
- Websitehttps://www.eagleus.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Checkpoint Therapeutics Inc | 103.00k | -51.85m | 51.03m | 23.00 | -- | -- | -- | 495.45 | -2.93 | -2.93 | 0.0055 | -0.4703 | 0.011 | -- | -- | 4,478.26 | -555.46 | -142.43 | -- | -342.79 | -- | -- | -50,336.89 | -6,554.97 | -- | -- | -- | -- | -46.35 | -50.61 | 17.21 | -- | -- | -- |
| Eledon Pharmaceuticals Inc | 0.00 | -40.33m | 51.12m | 20.00 | -- | 0.5979 | -- | -- | -1.82 | -1.82 | 0.00 | 3.45 | 0.00 | -- | -- | 0.00 | -44.35 | -38.44 | -47.03 | -39.80 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 54.16 | -- | -- | -- |
| Arca Biopharma Inc | 0.00 | -5.34m | 51.91m | 4.00 | -- | 1.40 | -- | -- | -0.3704 | -0.3704 | 0.00 | 2.55 | 0.00 | -- | -- | 0.00 | -13.19 | -27.78 | -13.49 | -29.38 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 46.21 | -- | -- | -- |
| Hcw Biologics Inc | 2.84m | -24.99m | 52.95m | 45.00 | -- | 3.75 | -- | 18.63 | -0.6953 | -0.6953 | 0.0791 | 0.3737 | 0.0755 | -- | 2.91 | 63,150.89 | -66.37 | -- | -78.58 | -- | 19.72 | -- | -879.53 | -- | -- | -90.86 | 0.319 | -- | -57.72 | -- | -67.74 | -- | -- | -- |
| Enzo Biochem Inc | 32.80m | -23.31m | 53.79m | 179.00 | -- | 0.749 | -- | 1.64 | -0.4699 | 0.6708 | 0.6586 | 1.40 | 0.3738 | 1.61 | 4.10 | 183,257.00 | -26.56 | -12.21 | -39.50 | -15.79 | 42.17 | 37.09 | -71.07 | -18.76 | 2.89 | -- | 0.0476 | -- | -4.85 | -21.01 | -23.02 | -- | 7.89 | -- |
| Intensity Therapeutics Inc | 0.00 | -11.86m | 53.81m | 5.00 | -- | 4.09 | -- | -- | -0.8653 | -0.8653 | 0.00 | 0.9601 | 0.00 | -- | -- | 0.00 | -110.62 | -- | -254.70 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -56.45 | -- | -- | -- |
| Eagle Pharmaceuticals Inc | 257.55m | 11.95m | 54.03m | 134.00 | 4.57 | 0.2161 | 1.65 | 0.2098 | 0.911 | 0.911 | 19.59 | 19.25 | 0.6549 | 1.55 | 2.56 | 1,922,022.00 | 3.04 | 6.37 | 4.04 | 7.98 | 69.84 | 71.86 | 4.64 | 7.85 | 1.67 | 3.55 | 0.2178 | 0.00 | 84.56 | 5.99 | 513.14 | -8.42 | -49.05 | -- |
| Avrobio Inc | 0.00 | 12.16m | 54.28m | 13.00 | 4.39 | 0.5703 | 4.25 | -- | 0.2756 | 0.2756 | 0.00 | 2.12 | 0.00 | -- | -- | 0.00 | 11.86 | -45.22 | 13.10 | -49.14 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 111.48 | -- | -66.27 | -- |
| Odonate Inc | 0.00 | -102.07m | 55.02m | 137.00 | -- | 2,028.85 | -- | -- | -13.59 | -13.59 | 0.00 | 9.27 | 0.00 | -- | -- | 0.00 | -66.98 | -58.36 | -83.00 | -65.14 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -12.99 | -- | -- | -- |
| Reneo Pharmaceuticals Inc | 0.00 | -77.39m | 55.81m | 8.00 | -- | 0.6299 | -- | -- | -2.52 | -2.52 | 0.00 | 2.65 | 0.00 | -- | -- | 0.00 | -71.78 | -- | -81.33 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -48.95 | -- | -- | -- |
| Immix Biopharma Inc | 0.00 | -15.43m | 56.22m | 14.00 | -- | 2.59 | -- | -- | -0.8803 | -0.8803 | 0.00 | 0.8235 | 0.00 | -- | -- | 0.00 | -89.54 | -- | -103.83 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -87.44 | -- | -- | -- |
| Benitec Biopharma Inc | 61.00k | -21.81m | 57.56m | 18.00 | -- | 1.16 | -- | 943.56 | -10.90 | -10.90 | 0.0304 | 5.97 | 0.0037 | -- | 1.01 | 3,388.89 | -131.16 | -83.43 | -174.32 | -98.77 | 172.13 | 96.86 | -35,754.10 | -468.04 | -- | -5,423.00 | 0.00 | -- | 2.74 | -53.84 | -7.44 | -- | -56.51 | -- |
| Cidara Therapeutics Inc | 63.91m | -22.93m | 57.61m | 69.00 | -- | -- | -- | 0.9016 | -0.2528 | -0.2528 | 0.7136 | -0.0906 | 1.12 | -- | 5.79 | 926,159.40 | -40.05 | -65.23 | -804.74 | -154.37 | 45.03 | -- | -35.88 | -100.61 | 0.8122 | -- | -- | -- | -0.8425 | -- | 31.72 | -- | 23.33 | -- |
Data as of Apr 26 2024. Currency figures normalised to Eagle Pharmaceuticals Inc's reporting currency: US Dollar USD
39.82%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Dec 2023 | 790.91k | 6.09% |
| Janus Henderson Investors US LLCas of 31 Dec 2023 | 775.53k | 5.97% |
| Brandes Investment Partners LPas of 31 Dec 2023 | 745.08k | 5.74% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 613.58k | 4.73% |
| Millennium Management LLCas of 31 Dec 2023 | 522.40k | 4.02% |
| AQR Capital Management LLCas of 31 Dec 2023 | 493.67k | 3.80% |
| LSV Asset Managementas of 31 Dec 2023 | 391.76k | 3.02% |
| Renaissance Technologies LLCas of 31 Dec 2023 | 294.45k | 2.27% |
| Acadian Asset Management LLCas of 31 Dec 2023 | 287.56k | 2.21% |
| Morgan Stanley & Co. LLCas of 31 Dec 2023 | 255.92k | 1.97% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
